Home > Healthcare > Medical Devices > Therapeutic Devices > Perfusion Systems Market
Perfusion Systems Market Size
Perfusion Systems Market size was valued at over USD 1.35 billion in 2023 and is projected to register around 4.5% CAGR between 2024 and 2032. This incremental growth rate is owing to increasing prevalence of cardiovascular and respiratory diseases coupled with technological advancements in perfusion systems. Increasing incidence of multiple organ failure among ageing population and rising number of organ transplantations is anticipated to drive the adoption of perfusion systems across the globe. The rising adoption of perfusion technology in drug discovery and development, tissue engineering, regenerative medicine, and the growing demand for biologics and personalized medicine will further propel the market growth.
The perfusion systems market has witnessed significant technological advancements to improve system performance, scalability, and automation. The integration of advanced sensors and control systems have enhanced process monitoring and control, leading to more precise and efficient cell and tissue cultures. Incrementally ageing population have augmented the demand for perfusion systems owing to risks such as multiple organ failure and other chronic ailments. Rising awareness regarding chronic conditions, organ transplantations and improved access to healthcare services have led to a surge in the demand for perfusion systems. Therefore, the perfusion systems industry is observing substantial growth and innovation, driven by the demand for better diagnosis and treatment of cardiovascular ailments, organ donations and technological advancements perfusion technologies.
Perfusion systems are specialized medical devices intended to support the growth and maintenance of cell cultures or tissues outside the natural environment. These systems provides a controlled environment with a continuous flow of oxygen, nutrients, growth factors, and other essential components necessary for their survival and optimal function of the cells and tissue.
Report Attributes | Details |
---|---|
Base Year: | 2023 |
Market Size in 2023: | USD 1.35 Billion |
Forecast Period: | 2024 to 2032 |
Forecast Period 2024 to 2032 CAGR: | 4.5% |
2032 Value Projection: | USD 2.02 Billion |
Historical Data for: | 2018 to 2023 |
No. of Pages: | 180 |
Tables, Charts & Figures: | 357 |
Segments covered: | Technique, Component, Application, End-use, and Region |
Growth Drivers: |
|
Pitfalls & Challenges: |
|
However, high cost associated with perfusion systems can pose a significant challenge and impede the market growth in the coming years. The high cost of perfusion systems makes it difficult for research laboratories, academic institutions, and healthcare facilities with limited budgets to afford these systems. Limited financial resources may hinder their ability to invest in perfusion technology, limiting the market's potential growth. In developing countries or regions with limited resources, the high cost of perfusion systems can present a significant barrier to the adoption. These markets may struggle to allocate sufficient funding to invest in expensive equipment, limiting the potential growth in these regions.
Moreover, the value proposition of perfusion systems, such as improved productivity, better control over culture conditions, and enhanced product quality, has increased the cost of these systems incrementally.
COVID-19 Impact
The recent outbreak of COVID-19 had negatively influenced the perfusion systems industry revenue, specifically during the initial phase of 2020. The coronavirus outbreak proliferated the disease burden and hampered several global businesses including the healthcare sector, during the pandemic phase. These conditions severely impacted the perfusion systems market growth. Several hospitals and healthcare facilities globally experienced a significant decline in patient visits for diagnosis and treatment of perfusion systems and other related chronic conditions. The COVID-19 pandemic has reduced visits to healthcare facilities, causing medical services in several countries to be delayed, including organ donation and other surgical procedures. The pandemic has disrupted global supply chains, causing delays in the production, delivery, and distribution of perfusion systems.
Restrictions on international trade, lockdown measures, and reduced workforce availability have affected the timely availability of components and raw materials necessary for manufacturing perfusion systems. These disruptions have slowed down production and hindered market growth. The pandemic has disrupted clinical trial activities, with many trials being postponed or halted due to safety concerns, limited patient access, and overwhelmed healthcare systems. The COVID-19 pandemic resulted in a precipitous decline in hospitalizations of chronic ailments. Due to the pandemic, many healthcare systems and hospitals had to prioritize resources and focus on treating COVID-19 patients.
As a result, elective procedures were often postponed or canceled. Thus, the COVID-19 pandemic had a negative impact on the perfusion systems market during 2020 which gained impetus in the later stages during 2021. Reducing COVID-19 infection rates and patients, as well as increased procedural volume, are expected to aid market growth in the approaching years.
Perfusion Systems Market Trends
Increasing prevalence of cardiovascular and respiratory diseases is anticipated to drive the market growth. Cardiovascular and respiratory diseases often lead to tissue damage and organ dysfunction. For instance, according to the Global Initiative for Chronic Obstructive Lung Disease – GOLD, in 2020, the incidence rate of lung cancer was around 2.2 million individuals and is forecasted to increase in the near future. Perfusion systems play a crucial role in the diagnosis and treatment of lung cancer and other chronic ailments by providing a controlled environment for the growth and development of tissues and organs for transplantation.
The increasing prevalence of cardiovascular and respiratory diseases drives the demand for tissue engineering and regenerative medicine, thereby boosting the perfusion systems market for perfusion systems. There is an increasing focus on personalized medicine, tailoring treatments to individual patients' specific characteristics. Perfusion systems play a role in this approach by facilitating the culture and testing of patient-specific cells or tissues for diagnosis and treatment optimization.
With cardiovascular and respiratory diseases being diverse in nature and manifestation, the demand for personalized medicine is set to grow, driving the utilization of perfusion systems. The treatment of cardiovascular and respiratory diseases often involves the use of biologics, such as therapeutic proteins, cell therapies, and gene therapies. Perfusion systems are integral to the bioprocessing of these products, ensuring optimal cell growth, viability, and productivity. Therefore, as the burden of cardiovascular and respiratory diseases continues to rise, the demand for advanced technologies in perfusion systems is anticipated to propel the market growth.
Perfusion Systems Market Analysis
Based on technique, the market is segmented as hypothermic machine perfusion, normothermic machine perfusion. The hypothermic machine perfusion dominated the perfusion systems market accounting over 65% business share in 2022. The increasing demand for hypothermic machine perfusion (HMP) can be attributed to several factors that drive the adoption and utilization of perfusion systems. HMP plays a vital role in organ preservation for transplantation, particularly for complex organs like the liver, kidney, and heart. It allows for extended preservation times compared to traditional static cold storage, reducing ischemic damage, and improving organ viability.
The increasing demand for organ transplantation, coupled with the need to improve transplant outcomes, drives the adoption of hypothermic machine perfusion. HMP permits for dynamic assessment of organ function and viability before transplantation. By continuously perfusing and monitoring the organ, HMP provides real-time data on parameters such as oxygen consumption, metabolic activity, and organ function. HMP enables the use of specialized preservation solutions that are continuously circulated through the organ during preservation.
Based on component, the perfusion systems market is segmented as oxygenators, heart-lung machine, perfusion pumps, monitoring system, bioreactor perfusion system and others. The oxygenators held a dominant business share and accounted for around USD 399 million in 2022. Oxygenators are a critical component of cardiopulmonary bypass (CPB) procedures, which are commonly used during cardiac surgeries. Oxygenators play a vital role in removing carbon dioxide and providing oxygen to the patient's blood during this process. The increasing number of cardiac surgeries and the need for CPB drive the demand for oxygenators, consequently impacting the market development. Oxygenators are also utilized in extracorporeal membrane oxygenation (ECMO) systems, that provide respiratory support to patients with severe respiratory failure.
With the rising prevalence of respiratory diseases and the need for advanced life support, the demand for oxygenators has been increasing, contributing to the growth of the perfusion systems market. Technological advancements have improved the design and performance of oxygenators significantly. Enhanced oxygen transfer capabilities, reduced priming volumes, and improved biocompatibility are some of the advancements that make oxygenators more efficient and reliable. These advancements coupled with ageing population, drives the adoption of oxygenators thereby fuelling industry growth.
Based on application, the perfusion systems market is segmented as cardiopulmonary perfusion system, cell perfusion system and ex-vivo organ perfusion system. The cardiopulmonary perfusion system captured a majority market share and is expected to grow at 4.7% CAGR till 2032. Cardiopulmonary perfusion systems are essential in cardiac surgeries as they temporarily take over the function of the heart and lungs, maintaining oxygenation and circulation during the procedure. These systems ensure the delivery of oxygenated blood to the patient's body while the heart is stopped for surgical intervention. The rising number of cardiac surgeries, including coronary artery bypass grafting (CABG), valve repair or replacement, and congenital heart defect corrections, drives the demand for cardiopulmonary perfusion systems.
The global burden of cardiovascular diseases, including conditions such as coronary artery disease, heart failure, and valvular diseases, continues to rise. Additionally, advancements in healthcare infrastructure and accessibility to advanced medical facilities in developing countries have led to an increased demand for cardiac surgeries. Cardiopulmonary perfusion systems help maintain stable physiological conditions during cardiac surgeries, reducing the risk of complications and improving patient outcomes.
Based on end-use, the perfusion systems market is segmented as hospitals, ambulatory surgical centers, and others. The hospitals segment acquired a dominant market share and accounted for around USD 623 million in 2022. Hospitals perform a range of advanced cardiac surgeries, such as coronary artery bypass grafting (CABG), heart valve repair or replacement, and congenital heart defect corrections. Perfusion systems are essential during these procedures, as they temporarily take over the function of the heart and lungs, maintaining oxygenation and circulation while the heart is stopped for surgical intervention. The increasing demand for these surgeries drives the need for perfusion systems in hospitals. Perfusion systems contribute to improved patient outcomes in cardiac surgeries.
Hospitals are increasingly adopting minimally invasive surgical techniques that incorporate specialized perfusion systems designed for smaller incisions and less invasive approaches. Hospitals that perform organ transplant surgeries require perfusion systems for organ preservation. In addition, increasing admissions with chronic disorders and growing disease related awareness initiatives along with the availability of highly skilled healthcare practitioners are some additional aspects that are fueling the expansion of the hospitals segment positively. Thus, availability and accessibility to advanced perfusion systems and better treatment & diagnosis coupled with the rising prevalence of chronic ailments will surge patient visits to hospitals, thereby propelling the segment revenue.
North America region held a dominant share in the global perfusion systems market and was valued at USD 477 million in 2022. This high market share is ascribed to a variety of factors, including the presence of significant industry players, an increase in the number of patients suffering from cardiovascular and respiratory diseases, an expanding elderly population, among others. Cardiovascular diseases, such as coronary artery disease, heart failure, and valvular disorders, are increasingly prevalent in North America. The region experiences a high burden of these conditions, leading to a greater demand for cardiovascular surgeries and interventions. Perfusions systems are critical for cardiac surgeries, including coronary artery bypass grafting (CABG) and valve repairs/replacements, which are common procedures performed to treat cardiovascular diseases.
Technological advancements, such as improved monitoring capabilities, better control systems, and enhanced biocompatibility, attract healthcare providers in North America to adopt the latest perfusion system technologies. The reimbursement landscape in the region plays a significant role in driving the demand for perfusion systems. Favorable reimbursement policies, coverage by insurance providers, and government healthcare programs facilitate the adoption of perfusion systems in hospitals and several healthcare facilities. Therefore, factors such as robust healthcare infrastructure, high prevalence of cardiovascular diseases, technological advancements, favorable reimbursement policies, focus on minimally invasive surgeries, and active research and clinical trials drives the increasing demand for perfusion systems in North America.
Perfusion Systems Market Share
Some of the major players operating in the perfusion systems market are :
- ALA Scientific Instruments, Inc.
- Bioptechs Inc.
- Cytiva
- Getinge AB
- Harvard Bioscience, Inc.
- Lifeline Scientific, Inc
- LivaNova
- Medtronic, plc
- Merck KGaA
- Nipro Corporation
- Repligen Corporation
- Spectrum Laboratories, Inc.
- Terumo Corporation
- XENIOS AG
- XVIVO Perfusion AB
These leading market players are implementing advanced technologies to cater to the large unmet needs of the consumers. These players focus on strategic partnerships, new product launch & commercialization for market expansion. Furthermore, these players are heavily investing in research that allows them to introduce innovative products and garner maximum revenue in the market.
Perfusion Systems Industry News:
- In February 2023, LivaNova PLC announced the launch of Essenz Perfusion System for cardiopulmonary bypass procedures in Europe. This systems incorporates advance heart-lung machine and a transformative patient monitor during cardiopulmonary bypass (CPB) procedures. This innovative product launch helped the company to expand their geographic presence and increase their customer base thereby generating business revenue.
- In September 2020, Cytiva announced the launch of Xcellerex Automated Perfusion System (APS) intended for upstream surgical procedures. This system is integrated with bioreactors for continuous upstream bioprocessing operations and is capable of automated filter switching, liquid management and cell bleed, that reduces risk for human error and increases process robustness. This strategic launch helped the company to increase their product portfolio and gain a competitive edge over its peers.
This perfusion systems market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue (USD Million) from 2018 to 2032, for the following segments:
Click here to Buy Section of this Report
By Technique
- Hypothermic Machine Perfusion
- Normothermic Machine Perfusion
By Component
- Oxygenators
- Heart-Lung Machine
- Perfusion Pumps
- Monitoring System
- Bioreactor Perfusion System
- Others
By Application
- Cardiopulmonary Perfusion System
- Cell Perfusion System
- Ex-Vivo Organ Perfusion System
By End-use
- Hospitals
- Ambulatory Surgical Centers
- Others
The above information is provided for the following regions and countries:
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- France
- Spain
- Italy
- Poland
- Sweden
- The Netherlands
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Indonesia
- Thailand
- Philippines
- Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Chile
- Peru
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Israel
- Egypt
- Turkey
Frequently Asked Questions (FAQ) :